Simon Ducharme
Overview
Explore the profile of Simon Ducharme including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
2397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yakoub Y, Gonzalez-Ortiz F, Ashton N, Dery C, Strikwerda-Brown C, St-Onge F, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14537.
PMID: 40008832
Introduction: We assessed the prognostic accuracy of plasma p-tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow-up of 5.65 years...
2.
Metz A, Zeighami Y, Ducharme S, Villeneuve S, Dadar M
Brain Commun
. 2025 Feb;
7(1):fcaf065.
PMID: 39990273
Frontotemporal dementia (FTD) is a prevalent form of early-onset dementia characterized by progressive neurodegeneration and encompasses a group of heterogeneous disorders. Due to overlapping symptoms, diagnosis of FTD and its...
3.
Sogorb-Esteve A, Weiner S, Simren J, Swift I, Bocchetta M, Todd E, et al.
Sci Transl Med
. 2025 Feb;
17(784):eadm9654.
PMID: 39908349
We used an untargeted mass spectrometric approach, tandem mass tag proteomics, for the identification of proteomic signatures in genetic frontotemporal dementia (FTD). A total of 238 cerebrospinal fluid (CSF) samples...
4.
Smith E, Phillips N, Feldman H, Borrie M, Ganesh A, Henri-Bhargava A, et al.
J Prev Alzheimers Dis
. 2025 Feb;
12(3):100068.
PMID: 39893139
Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To...
5.
Andrews D, Ducharme S, Chertkow H, Sormani M, Collins D
Alzheimers Dement
. 2025 Jan;
21(1):e14467.
PMID: 39887549
Introduction: The phase 3 trial CLARITY AD found lecanemab slowed cognitive decline by 27%. However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or...
6.
Coleman K, Berry S, Cummings J, Hsiung G, Laforce R, Huey E, et al.
Lancet Neurol
. 2025 Jan;
24(2):128-139.
PMID: 39862881
Background: No treatments exist for apathy in people with frontotemporal dementia. Previously, in a randomised double-blind, placebo-controlled, dose-finding study, intranasal oxytocin administration in people with frontotemporal dementia improved apathy ratings...
7.
Chertkow H, Phillips N, Rockwood K, Anderson N, Andrew M, Bartha R, et al.
J Alzheimers Dis
. 2024 Dec;
102(3):535-561.
PMID: 39636028
The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014,...
8.
van Paassen D, Hartog L, de Boer S, Vijverberg E, Ducharme S, Pijnenburg Y, et al.
Eur J Neurol
. 2024 Nov;
32(1):e16537.
PMID: 39607834
Background And Purpose: Behavioral variant frontotemporal dementia (bvFTD) is essentially characterized by progressive changes in personality and cognition. Clinically, bvFTD presents with often profound behavioral symptomatology. Despite the high burden...
9.
Best P, Van Swieten J, Jiskoot L, Moreno F, Sanchez-Valle R, Laforce Jr R, et al.
Neurology
. 2024 Nov;
103(11):e209829.
PMID: 39527773
Background And Objectives: Sleep dysfunction is common in patients with neurodegenerative disorders; however, its neural underpinnings remain poorly characterized in genetic frontotemporal dementia (FTD). Hypothalamic nuclei important for sleep regulation...
10.
Borrego-Ecija S, Junca-Parella J, Vandebergh M, Perez Millan A, Balasa M, Llado A, et al.
Neurology
. 2024 Nov;
103(11):e209944.
PMID: 39527772
Background And Objectives: Pathogenic variants in the gene cause frontotemporal dementia (FTD-) with marked brain asymmetry. This study aims to assess whether the disease progression of FTD- depends on the...